MX377159B - Inhibidor de bromodominio. - Google Patents
Inhibidor de bromodominio.Info
- Publication number
- MX377159B MX377159B MX2017013501A MX2017013501A MX377159B MX 377159 B MX377159 B MX 377159B MX 2017013501 A MX2017013501 A MX 2017013501A MX 2017013501 A MX2017013501 A MX 2017013501A MX 377159 B MX377159 B MX 377159B
- Authority
- MX
- Mexico
- Prior art keywords
- methylisoquinolin
- methylsulfonylphenyl
- cyclopropylmethoxy
- pharmaceutical compositions
- inhibitor
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 5
- UWZAJPITKGWMFJ-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one Chemical compound Cn1cc(-c2cc(ccc2OCC2CC2)S(C)(=O)=O)c2ccccc2c1=O UWZAJPITKGWMFJ-UHFFFAOYSA-N 0.000 abstract 4
- 229920000642 polymer Polymers 0.000 abstract 3
- 229940125763 bromodomain inhibitor Drugs 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- -1 crystalline forms Chemical compound 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000010922 spray-dried dispersion Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describe en la presente solicitud el inhibidor de bromodominio 4-[2- (ciclopropilmetoxi)-5-metilsulfonilfeni1]-2-metilisoquinolin-1-ona, que incluye sus formas cristalinas, formas amorfas, solvatos e hidratos, al igual que composiciones farmacéuticas que incluyen este inhibidor de bromodominio. En algunas formas de realización, la composición farmacéutica comprende 4--[2-(ciclopropilmetoxi)-5- metilsulfonilfeni1]-2-metilisoquinolin-1-ona que ha sido procesada por medio de la micronización o la dispersión secada por pulverización. En algunas formas de realización, la composición farmacéutica además comprende por lo menos un polímero. En algunas formas de realización, las composiciones farmacéuticas comprenden una matriz de polimero sólida que comprende 4-(2- (ciclopropilmetoxi)-5-metilsulfonilfeni11-2-metilisoquinolin-1-ona y por lo menos un polímero. Las composiciones farmacéuticas que comprenden 4-[2- (ciclopropilmetoxi)-5-metilsulfonilfenil]-2-metilisoquinolin-1-ona son útiles para el tratamiento de cáncer o enfermedad neoplásica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562151205P | 2015-04-22 | 2015-04-22 | |
| PCT/US2016/029029 WO2016172618A1 (en) | 2015-04-22 | 2016-04-22 | Bromodomain inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017013501A MX2017013501A (es) | 2018-02-09 |
| MX377159B true MX377159B (es) | 2025-03-07 |
Family
ID=57143581
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010899A MX390077B (es) | 2015-04-22 | 2016-04-22 | Inhibidor de bromodominio. |
| MX2017013501A MX377159B (es) | 2015-04-22 | 2016-04-22 | Inhibidor de bromodominio. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010899A MX390077B (es) | 2015-04-22 | 2016-04-22 | Inhibidor de bromodominio. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20160310423A1 (es) |
| EP (1) | EP3285770A4 (es) |
| JP (1) | JP2018513863A (es) |
| KR (1) | KR20170139119A (es) |
| CN (1) | CN107613981A (es) |
| AR (1) | AR104340A1 (es) |
| AU (1) | AU2016252992A1 (es) |
| BR (1) | BR112017022691A2 (es) |
| CA (1) | CA2983446C (es) |
| CL (1) | CL2017002679A1 (es) |
| CO (1) | CO2017011482A2 (es) |
| EA (1) | EA201792317A1 (es) |
| EC (1) | ECSP17071545A (es) |
| HK (1) | HK1243948A1 (es) |
| IL (1) | IL255120B (es) |
| MX (2) | MX390077B (es) |
| PE (1) | PE20180036A1 (es) |
| PH (1) | PH12017501933A1 (es) |
| SG (1) | SG11201708627TA (es) |
| TW (1) | TW201642860A (es) |
| WO (1) | WO2016172618A1 (es) |
| ZA (1) | ZA201707186B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104259A1 (es) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| US10702517B2 (en) | 2015-04-22 | 2020-07-07 | Celgene Quanticel Research, Inc. | Bromodomain inhibitor |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| CN110099685A (zh) * | 2016-10-20 | 2019-08-06 | 赛尔基因光迪斯研究公司 | 溴结构域抑制剂 |
| ES2907840T3 (es) | 2016-10-27 | 2022-04-26 | Celgene Quanticel Res Inc | Terapia combinada de inhibidor de proteína de bromodominio y extraterminal |
| KR20210058817A (ko) * | 2018-07-23 | 2021-05-24 | 셀젠 콴티셀 리서치, 인크. | 브로모도메인 억제제의 제조 방법 |
| US20220265618A1 (en) * | 2021-02-22 | 2022-08-25 | Celgene Quanticel Research, Inc. | Methods of treating prostate cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| RS63733B1 (sr) * | 2013-10-18 | 2022-12-30 | Celgene Quanticel Research Inc | Inhibitori bromodomena |
| CN110099685A (zh) * | 2016-10-20 | 2019-08-06 | 赛尔基因光迪斯研究公司 | 溴结构域抑制剂 |
-
2016
- 2016-04-19 TW TW105112168A patent/TW201642860A/zh unknown
- 2016-04-21 AR ARP160101100A patent/AR104340A1/es unknown
- 2016-04-22 SG SG11201708627TA patent/SG11201708627TA/en unknown
- 2016-04-22 CA CA2983446A patent/CA2983446C/en active Active
- 2016-04-22 BR BR112017022691-0A patent/BR112017022691A2/pt not_active Application Discontinuation
- 2016-04-22 CN CN201680032770.1A patent/CN107613981A/zh active Pending
- 2016-04-22 JP JP2017554566A patent/JP2018513863A/ja active Pending
- 2016-04-22 KR KR1020177033575A patent/KR20170139119A/ko active Pending
- 2016-04-22 EA EA201792317A patent/EA201792317A1/ru unknown
- 2016-04-22 MX MX2020010899A patent/MX390077B/es unknown
- 2016-04-22 MX MX2017013501A patent/MX377159B/es active IP Right Grant
- 2016-04-22 EP EP16784024.8A patent/EP3285770A4/en not_active Withdrawn
- 2016-04-22 PE PE2017002306A patent/PE20180036A1/es not_active Application Discontinuation
- 2016-04-22 HK HK18103550.6A patent/HK1243948A1/zh unknown
- 2016-04-22 WO PCT/US2016/029029 patent/WO2016172618A1/en not_active Ceased
- 2016-04-22 US US15/136,761 patent/US20160310423A1/en not_active Abandoned
- 2016-04-22 AU AU2016252992A patent/AU2016252992A1/en not_active Abandoned
-
2017
- 2017-10-18 IL IL255120A patent/IL255120B/en active IP Right Grant
- 2017-10-20 CL CL2017002679A patent/CL2017002679A1/es unknown
- 2017-10-23 PH PH12017501933A patent/PH12017501933A1/en unknown
- 2017-10-23 ZA ZA2017/07186A patent/ZA201707186B/en unknown
- 2017-10-26 EC ECIEPI201771545A patent/ECSP17071545A/es unknown
- 2017-11-08 CO CONC2017/0011482A patent/CO2017011482A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016252992A1 (en) | 2017-11-09 |
| NZ736630A (en) | 2024-03-22 |
| EP3285770A1 (en) | 2018-02-28 |
| CN107613981A (zh) | 2018-01-19 |
| MX390077B (es) | 2025-03-20 |
| KR20170139119A (ko) | 2017-12-18 |
| WO2016172618A1 (en) | 2016-10-27 |
| JP2018513863A (ja) | 2018-05-31 |
| IL255120B (en) | 2021-03-25 |
| CL2017002679A1 (es) | 2018-05-25 |
| CA2983446C (en) | 2024-04-09 |
| MX2020010899A (es) | 2022-02-15 |
| BR112017022691A2 (pt) | 2018-07-17 |
| PE20180036A1 (es) | 2018-01-09 |
| US20160310423A1 (en) | 2016-10-27 |
| ECSP17071545A (es) | 2017-12-01 |
| AR104340A1 (es) | 2017-07-12 |
| EP3285770A4 (en) | 2018-10-31 |
| SG11201708627TA (en) | 2017-11-29 |
| CO2017011482A2 (es) | 2018-01-31 |
| IL255120A0 (en) | 2017-12-31 |
| CA2983446A1 (en) | 2016-10-27 |
| TW201642860A (zh) | 2016-12-16 |
| HK1243948A1 (zh) | 2018-07-27 |
| EA201792317A1 (ru) | 2018-03-30 |
| MX2017013501A (es) | 2018-02-09 |
| ZA201707186B (en) | 2019-01-30 |
| PH12017501933A1 (en) | 2018-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX390077B (es) | Inhibidor de bromodominio. | |
| EP3891149A4 (en) | RET INHIBITOR, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | |
| MX2022009998A (es) | Formas cristalinas de la n-(4-(4-(ciclopropilmetil)piperazin-1- carbonil)fenil)quinolin-8-sulfonamida. | |
| MX2021001091A (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington. | |
| CR20200545A (es) | Inhibidores magl | |
| MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
| EP4292650A3 (en) | Heterocyclic compounds as immunomodulators | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| WO2015168466A8 (en) | Inhibitors of lysine specific demethylase-1 | |
| BR112017003658A2 (pt) | composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica. | |
| PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
| MY192861A (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| MX2021003643A (es) | Derivados de terpenoides y usos de los mismos. | |
| BR112017024633A2 (pt) | novo amidoeteroaril aroil hidrazida etino | |
| AR109859A1 (es) | Inhibidor de bromodominio | |
| MX2019001771A (es) | Composición farmacéutica sólida que comprende el sofosbuvir amorfo. | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| MX2019004187A (es) | Inhibidores de bromodominios. | |
| CO2020003134A2 (es) | Moduladores de la expresión de enac | |
| CO2019007671A2 (es) | Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer | |
| MX2020006472A (es) | Derivados de glucosamina para la prevencion o tratamiento de trastornos articulares. | |
| WO2019151965A3 (en) | Solid oral pharmaceutical compositions comprising apixaban | |
| BR112022008365A2 (pt) | Inibidores de cd73 | |
| KR102144264B9 (ko) | 익모 추출물을 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
| EA201991524A1 (ru) | Производные бензоксазола в качестве иммуномодуляторов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |